UA118587C2 - Фармацевтично прийнятні солі енантіомерів пірліндолу для застосування в медицині - Google Patents

Фармацевтично прийнятні солі енантіомерів пірліндолу для застосування в медицині

Info

Publication number
UA118587C2
UA118587C2 UAA201611335A UAA201611335A UA118587C2 UA 118587 C2 UA118587 C2 UA 118587C2 UA A201611335 A UAA201611335 A UA A201611335A UA A201611335 A UAA201611335 A UA A201611335A UA 118587 C2 UA118587 C2 UA 118587C2
Authority
UA
Ukraine
Prior art keywords
medicine
pharmaceutically acceptable
acceptable salts
pirlindole
pirlindole enantiomers
Prior art date
Application number
UAA201611335A
Other languages
English (en)
Inventor
Філіпі Ауґушту Еуженью Пардал
Педрозу Педру Філіпі Еуфразью
Пекореллі Сузана Маркеш Алмейда
Кайшаду Карлуш Алберту Еуфразью Казіміру
Ана Софья да Консейсан Лопеш
Жуан Карлуш Рамуш Даміл
Олівейра Сантуш Педру Паулу де Ласерда Е
Original Assignee
Текнімеді Сос'Єдаді Текніку-Медісінал С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Текнімеді Сос'Єдаді Текніку-Медісінал С.А. filed Critical Текнімеді Сос'Єдаді Текніку-Медісінал С.А.
Publication of UA118587C2 publication Critical patent/UA118587C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Винахід стосується фармацевтично прийнятних солей сполук енантіомерно чистого (R)-пірліндолу та (S)-пірліндолу, які мають підвищений профіль біопридатності для застосування в медицині.
UAA201611335A 2014-05-09 2014-05-09 Фармацевтично прийнятні солі енантіомерів пірліндолу для застосування в медицині UA118587C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000026 WO2015171002A1 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine

Publications (1)

Publication Number Publication Date
UA118587C2 true UA118587C2 (uk) 2019-02-11

Family

ID=50819928

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201611335A UA118587C2 (uk) 2014-05-09 2014-05-09 Фармацевтично прийнятні солі енантіомерів пірліндолу для застосування в медицині

Country Status (19)

Country Link
US (1) US10226460B2 (uk)
EP (2) EP3139926A1 (uk)
JP (1) JP6400121B2 (uk)
KR (1) KR102276281B1 (uk)
CN (1) CN106413713B (uk)
AU (1) AU2014393487B2 (uk)
CA (1) CA2948595C (uk)
DK (1) DK3831385T3 (uk)
EC (1) ECSP16086196A (uk)
IL (1) IL248852B (uk)
MA (1) MA39450B2 (uk)
MX (1) MX2016014704A (uk)
NZ (1) NZ726127A (uk)
PH (1) PH12016502235A1 (uk)
RU (1) RU2706688C2 (uk)
SA (1) SA516380258B1 (uk)
TN (1) TN2016000495A1 (uk)
UA (1) UA118587C2 (uk)
WO (1) WO2015171002A1 (uk)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2695607C2 (ru) 2014-05-09 2019-07-24 Текнимеди Сосьедади Текнику-Медисинал С.А. (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине
HUE035071T2 (en) * 2014-05-09 2018-05-02 Tecnimede Sociedade Tecnico Medicinal S (S) -pirlindole and its pharmaceutically acceptable salts for use in medicine
EP3392250A1 (en) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of piperazine ring for the synthesis of pyrazinocarbazole derivatives
EP3392251A1 (en) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of pirlindole enantiomers and its salts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO166131C (no) 1985-06-20 1991-06-05 Daiichi Seiyaku Co Analogifremgangsmaate for fremstilling av s(-)-pyridobenzoksazinforbindelser.
CA2500662A1 (en) * 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
BRPI0922871A2 (pt) * 2008-12-11 2016-11-16 Biovista Inc metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos
WO2014062621A1 (en) * 2012-10-15 2014-04-24 Stc.Unm Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
RU2695607C2 (ru) * 2014-05-09 2019-07-24 Текнимеди Сосьедади Текнику-Медисинал С.А. (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине
HUE035071T2 (en) * 2014-05-09 2018-05-02 Tecnimede Sociedade Tecnico Medicinal S (S) -pirlindole and its pharmaceutically acceptable salts for use in medicine
ES2753403T3 (es) * 2014-05-09 2020-04-08 Tecnimede Sociedade Tecnico Medicinal S Procedimiento para la obtención de enantiómeros de pirlindol ópticamente activos y sales de los mismos

Also Published As

Publication number Publication date
JP6400121B2 (ja) 2018-10-03
AU2014393487A1 (en) 2016-11-24
DK3831385T3 (da) 2024-08-26
EP3139926A1 (en) 2017-03-15
WO2015171002A1 (en) 2015-11-12
RU2706688C2 (ru) 2019-11-20
PH12016502235A1 (en) 2017-01-09
RU2016148174A3 (uk) 2018-06-14
IL248852A0 (en) 2017-01-31
KR20170002433A (ko) 2017-01-06
ECSP16086196A (es) 2017-02-24
RU2016148174A (ru) 2018-06-14
SA516380258B1 (ar) 2019-11-04
NZ726127A (en) 2019-03-29
MA39450A1 (fr) 2017-08-31
MX2016014704A (es) 2017-05-23
CA2948595A1 (en) 2015-11-12
AU2014393487B2 (en) 2020-01-02
IL248852B (en) 2020-05-31
CN106413713A (zh) 2017-02-15
MA39450B2 (fr) 2021-10-29
EP3831385A1 (en) 2021-06-09
US20170143710A1 (en) 2017-05-25
CN106413713B (zh) 2020-07-14
CA2948595C (en) 2021-07-13
TN2016000495A1 (en) 2018-04-04
KR102276281B1 (ko) 2021-07-13
US10226460B2 (en) 2019-03-12
JP2017514882A (ja) 2017-06-08
EP3831385B1 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
IL247901A0 (en) Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
EP3528737A4 (en) MEDICAL STAND
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EP3302485A4 (en) CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNOMES
PH12016502235A1 (en) Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
EP3436120A4 (en) ORAL MEDICAL DEVICE
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
PH12016502234B1 (en) Process for obtaining optically active pirlindole enantiomers and salts thereof
HK1251476A1 (zh) 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽
EP3137071A4 (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
ZA201907515B (en) Process for the preparation of pirlindole enantiomers and its salts
SI3612535T1 (sl) Postopek za pripravo pirlindolnih enantiomerov in njihovih soli
PL3612535T3 (pl) Sposób otrzymywania enancjomerów pirlindolu i jego soli
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
EP3138559A4 (en) Drug for treatment of tinnitus patients
EP3122356A4 (en) Treatment of parkinson's disease through arfgap1 inhibition using substituted piperazine derivatives